100 related articles for article (PubMed ID: 3214968)
1. Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure.
Stamatakis G; Montes C; Trouvin JH; Farinotti R; Fessi H; Kenouch S; Méry JP
Clin Nephrol; 1988 Oct; 30(4):230-4. PubMed ID: 3214968
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic study of pyrazinamide and pyrazinoic acid in subjects with normal renal function and patients with renal failure].
Vayre P; Chambraud E; Fredj G; Thuillier A
Therapie; 1989; 44(1):1-4. PubMed ID: 2734715
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
Lacroix C; Tranvouez JL; Phan Hoang T; Duwoos H; Lafont O
Arzneimittelforschung; 1990 Jan; 40(1):76-9. PubMed ID: 2340003
[TBL] [Abstract][Full Text] [Related]
5. Changes in erythromycin pharmacokinetics induced by renal failure.
Kanfer A; Stamatakis G; Torlotin JC; Fredj G; Kenouch S; Méry JP
Clin Nephrol; 1987 Mar; 27(3):147-50. PubMed ID: 3494560
[TBL] [Abstract][Full Text] [Related]
6. Haemodialysis of pyrazinamide in uraemic patients.
Lacroix C; Hermelin A; Guiberteau R; Guyonnaud C; Nouveau J; Duwoos H; Lafont O
Eur J Clin Pharmacol; 1989; 37(3):309-11. PubMed ID: 2612545
[TBL] [Abstract][Full Text] [Related]
7. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
8. Profound mishandling of protein glycation degradation products in uremia and dialysis.
Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
[TBL] [Abstract][Full Text] [Related]
9. Effect of hemodialysis on ceftazidime pharmacokinetics.
Nikolaidis P; Tourkantonis A
Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
Teichert J; Tuemmers T; Achenbach H; Preiss C; Hermann R; Ruus P; Preiss R
J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
[TBL] [Abstract][Full Text] [Related]
13. [Simultaneous microdetermination of pyrazinamide and pyrazinoic acid by liquid chromatography].
Lacroix C; Langlois B; Ménager S; Lafont O
Ann Biol Clin (Paris); 1987; 45(3):297-9. PubMed ID: 3662137
[TBL] [Abstract][Full Text] [Related]
14. [The excretion of ascorbic acid and its metabolites in uremia and hemodialysis].
Bakaev VV; Efremov AV
Patol Fiziol Eksp Ter; 2000; (2):22-4. PubMed ID: 10846906
[TBL] [Abstract][Full Text] [Related]
15. Oxalic Acid as a uremic toxin.
Mydlík M; Derzsiová K
J Ren Nutr; 2008 Jan; 18(1):33-9. PubMed ID: 18089441
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects.
Lacroix C; Hoang TP; Nouveau J; Guyonnaud C; Laine G; Duwoos H; Lafont O
Eur J Clin Pharmacol; 1989; 36(4):395-400. PubMed ID: 2737233
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
Eriksson T; Höglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA
J Pharm Pharmacol; 2003 Dec; 55(12):1701-6. PubMed ID: 14738599
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
[TBL] [Abstract][Full Text] [Related]
19. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis.
Shahbazian H; Zand Moghadam A; Ehsanpour A; Khazaali M
Iran J Kidney Dis; 2009 Jul; 3(3):151-5. PubMed ID: 19617664
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis.
Mugabo P; Mulubwa M
Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):519-530. PubMed ID: 30617957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
